Idiopathic Generalized Epilepsy Syndromes
Recruiting · NCT06388174 · Observational (researchers observe without assigning treatment) · Lead sponsor: Shen Chun-Hong
View the official record on ClinicalTrials.gov →What this trial is about
The idiopathic generalized epilepsies (IGEs) have historically included the syndromes childhood absence epilepsy (CAE), juvenile absence epilepsy (JAE), juvenile myoclonic epilepsy (JME), and epilepsy with generalized tonic-clonic seizures alone (GTCA). Recognition of the IGEs is important for clinical care, as it informs diagnosis, prevents unnecessary investigation, allows optimal selection of anti-seizure medications (ASMs), and provides prognostic guidance. According to the new ILAE definition in 2022, the study aims to describe the clinical features, electroencephalographic, imaging findings and long-term prognosis.
Who can take part
Inclusion criteria
- Patients are consecutively and prospectively enrolled from epilepsy center, with newly diagnosed epilepsy or established epilepsy.
- Patients have a diagnosis of idiopathic generalized epilepsy (IGE), according to the 2022 diagnostic criteria.
- Comprehensive clinical information is collected, and 24 hour video-electroencephalography is performed.
- Sign the informed consent forms.
Exclusion criteria
- Other epilepsy syndromes are considered during follow-up, such as genetic generalized epilepsy.
- Lost to follow-up
Where it is running
1 location listed.
- 2nd Affiliated Hospital, School of Medicine, Zhejiang University, China - Hangzhou, Zhejiang, China